Visual performance after implantation of a new trifocal IOL with an advanced hydrophobic acrylic biomaterial.

PURPOSE: To evaluate the one-year efficacy and safety of the one-piece multifocal intraocular lens (IOL) Clareon PanOptix CNWT (Alcon, Fort Worth, TX, USA).

SETTING

Department of Ophthalmology, Goethe-University, Frankfurt, Germany.

DESIGN

A prospective, single-centre, single-arm, interventional study.

METHODS

Cataract patients underwent bilateral implantation of a Clareon PanOptix multifocal IOL following phacoemulsification. Examinations included manifest refraction, uncorrected visual acuity (UCVA) and distance-corrected visual acuity (DCVA) at 4m, 80cm, 60cm, 40cm, and 30cm, defocus test, contrast sensitivity (CS) under photopic and mesopic conditions and a questionnaire on subjective quality of vision (QoV), optical phenomena, and spectacle independence. The primary outcome was visual acuity after 12 months post operatively.

RESULTS

The binocular UCVA was -0.04 ± 0.08 logMAR and at intermediate (80cm and 60cm) and near (40cm and 30cm) -0.03 ± 0.05, -0.04 ± 0.11 and 0.05 ± 0.11, 0.19 ± 0.12 logMAR, respectively. The binocular distance-corrected defocus curve showed a peak at 0.0 D and -2.0 D with -0.07 and -0.02 logMAR, and between +0.50 and -3.00 D within 0.10 logMAR. At 12 months, there was no evidence of glistenings in any eye. Twenty-four (89%) participants would choose the IOL again and 23/27 (85%) would recommend the IOL to others.

CONCLUSION

The trifocal Clareon PanOptix IOL provides patients with good visual performance and spectacle independence at all distances without evidence of IOL glistenings.